Alaunos Therapeutics prices direct offering at $1.46 per share

Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced a registered direct offering priced at-the-market under Nasdaq rules, involving the sale of 380,469 shares of common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at $1.46 per share.

The offering is expected to generate aggregate gross proceeds of approximately $1,120,000 before placement agent fees and other expenses. The company said it intends to use net proceeds primarily for general working capital and corporate purposes.

The offering is expected to close on or about September 21, 2026, subject to customary closing conditions. Dawson James Securities, Inc. is serving as the sole placement agent.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on November 11, 2025, which became effective December 1, 2025.

Alaunos Therapeutics is a biotechnology company developing ALN1003, an oral small-molecule candidate being evaluated for obesity and metabolic disorders.

You May Also Be Interested In

• InnovAge stockholders price secondary offering of 10M shares at $9.25
• Solaris Energy prices upsized $1.25B senior notes offering
• Helus Pharma shareholders approve name change from Cybin Inc.